510(k) · Cleared
ClearedLyphochek Tumor Marker Control, Model 580
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Bio-Rad · JJY Multi-Analyte Controls, All Kinds (Assayed)
Cleared on Sep 2, 1999 as substantially equivalent to K983807 (Bio-Rad, 1998) after a 66-day review. Its family tree reaches back 2 generations to 1994. 7 later devices descend from it.
- Decided
- Sep 2, 1999
- Review
- 66 days
- Class
- Class I
- Product code
- JJY
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 2 generations to K940433 (1994). 7 later devices descend from it, 1 citing it directly.
- Root · 2 generations backK940433 Doa Liquid Drugs of Abuse Controls Levls 2,3,& 4,G2,G3,& G4Medical Analysis Systems, Inc. · 1994
- 1 generation backK983807 Lyphochek Tumor Marker Control, Model #580Bio-Rad · 1998
- This deviceK992172 Lyphochek Tumor Marker Control, Model 580Bio-Rad · 1999
- Descendant · cites it directly · 6 of its ownK011579 Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580Bio-Rad · 2001
- Descendant · 2 generations on · 2 of its ownK071675 Liquichek Tumor Marker ControlBio-Rad Laboratories · 2007
- Descendant · 2 generations on · 1 of its ownK082036 Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and MinipakBio-Rad Laboratories · 2008
- Descendant · 3 generations on · 0 of its ownK163015 Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker…Bio-Rad Laboratories · 2017
- Descendant · 3 generations on · 0 of its ownK141073 Liquichek Tumor Marker ControlBio-Rad Laboratories · 2014
Showing 5 of 7 descendants. See all descendants
Descendants cleared per year
Most influential descendants
Showing 5 of 7 · See all- K011579Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580Bio-Rad · 2001 · cites it directly6descendants
- K071675Liquichek Tumor Marker ControlBio-Rad Laboratories · 2007 · 2 generations on2descendants
- K082036Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and MinipakBio-Rad Laboratories · 2008 · 2 generations on1descendant
- K163015Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker Control-Level 2…Bio-Rad Laboratories · 2017 · 3 generations on0descendants
- K141073Liquichek Tumor Marker ControlBio-Rad Laboratories · 2014 · 3 generations on0descendants
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −2 | K940433 | Doa Liquid Drugs of Abuse Controls Levls 2,3,& 4,G2,G3,& G4 | Medical Analysis Systems, Inc. | 1994 | — |
| −1 | K983807 | Lyphochek Tumor Marker Control, Model #580 | Bio-Rad | 1998 | — |
| 0 (this device) | K992172 | Lyphochek Tumor Marker Control, Model 580 | Bio-Rad | 1999 | — |
| +1 | K011579 | Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580 | Bio-Rad | 2001 | — |
| +2 | K071675 | Liquichek Tumor Marker Control | Bio-Rad Laboratories | 2007 | — |
| +2 | K082036 | Lyphochek Tumor Market Plus Control Level 1, 2 and 3 and Minipak | Bio-Rad Laboratories | 2008 | — |
| +3 | K163015 | Liquichek Tumor Marker Control-Level 1; Liquichek Tumor Marker Control-Level… | Bio-Rad Laboratories | 2017 | — |
| +3 | K141073 | Liquichek Tumor Marker Control | Bio-Rad Laboratories | 2014 | — |
Descendants by year cleared
| Year cleared | Devices | With a Class I recall |
|---|---|---|
| 2001 | 1 | 0 |
| 2004 | 1 | 0 |
| 2007 | 1 | 0 |
| 2008 | 1 | 0 |
| 2010 | 1 | 0 |
| 2014 | 1 | 0 |
| 2017 | 1 | 0 |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in JJY? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
- Candidate predicates for a device like this, rankedin the report
- Recall history across each candidate’s familyin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | K983807 | Lyphochek Tumor Marker Control, Model #580Summary page 1…Control, All Kinds (Assayed and Unassayed) Devices to Which Substantial Equivalence is Claimed Lyphochek Tumor Marker Control Bio-Rad Laboratories Irvine, California K983807 Statement of Intended Use Lyphochek Tumor Marker Control is intended for use as an assayed quality control serum to monitor the… | 1998 |
What descends from it? (7)
1 later device cites it directly; ranked here by how many devices descend from each in turn.
| Number | Device | Decided | Descendants |
|---|---|---|---|
| K011579 | Lyphochek Tumor Marker Control, Levels 1 and 2, 2ML, Model 580 | 2001 | 6 |
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- The line of descent spans 5 years and passes through 2 companies; a new generation was cleared every 4.4 years on median.
- None of the 2 ancestors has a recall.
- Of its descendants, K011579 (Bio-Rad, 2001) has gone furthest, with 6 descendants of its own.
How does its category compare?
All JJY devicesJJY Multi-Analyte Controls, All Kinds (Assayed): FDA decisions, review times, recalls and adverse event reports over 20 years.
FDA decisions per year · JJY
3in 2017
2026 to Oct 25, outlined.
Median 510(k) review, days · JJY
78in 2017
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · JJY
2in 2025
Class I (0 since 2007) Class II/III not classified
Adverse event reports per year · JJY
13in 2025
MAUDE reports naming product code JJY, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 11 | 49 | 5 | 2 |
| 2008 | 7 | 54 | 0 | 1 |
| 2009 | 8 | 80 | 2 | 3 |
| 2010 | 10 | 109 | 6 | 3 |
| 2011 | 14 | 120 | 1 | 6 |
| 2012 | 13 | 40 | 3 | 20 |
| 2013 | 16 | 82 | 2 | 5 |
| 2014 | 10 | 49 | 2 | 4 |
| 2015 | 4 | 153 | 1 | 4 |
| 2016 | 1 | — | 3 | 13 |
| 2017 | 3 | 78 | 4 | 12 |
| 2018 | 0 | — | 3 | 7 |
| 2019 | 0 | — | 4 | 1 |
| 2020 | 0 | — | 6 | 7 |
| 2021 | 0 | — | 0 | 1 |
| 2022 | 0 | — | 3 | 0 |
| 2023 | 0 | — | 3 | 4 |
| 2024 | 0 | — | 0 | 1 |
| 2025 | 0 | — | 2 | 13 |
| 2026 | 0 | — | 1 | — |
What is it indicated for?
Lyphochek Tumor Marker Control is intended for use as an assayed quality control serum to monitor the precision of laboratory testing procedures for the analytes listed in the package insert.
Indications for use read by OCR from a scanned FDA summary, so letters may be misread. Check the PDF before quoting it.
https://510kreport.com/device/K992172 · printed Nov 6, 2026
Cite this page
510(k) Report. “K992172: Lyphochek Tumor Marker Control, Model 580.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K992172
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026